This trial will test whether Tezepelumab can help reduce oral steroid use in people with severe asthma, who are already taking them with or without other asthma medications.
2 Primary · 13 Secondary · Reporting Duration: At Week 52
Side Effects for
1 Treatment Group
1 of 1
300 Total Participants · 1 Treatment Group
Primary Treatment: Tezepelumab · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18 - 80 · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Research Site: < 48 hours
Average response time
- < 2 Days
Frequently Asked Questions
How many people are participating in this trial at any given time?
"Yes, as the listing on clinicaltrials.gov indicates, this study is recruiting patients. The trial was originally posted on May 17th, 2022 and has been edited most recently on November 4th of the same year. Currently, 8 different locations are looking for a total of 323 participants." - Anonymous Online Contributor
Are there any participants needed for this clinical trial at the moment?
"Yes, the information on clinicaltrials.gov suggests that this study is recruiting patients as of the most recent update on 11/4/2022. The trial was first posted 5/17/2022 and is enrolling 323 participants between 8 locations." - Anonymous Online Contributor
Who meets the requirements to be a test subject in this experiment?
"This trial is recruiting 323 participants who have asthma and are between the ages of 18 and 80. The following criteria must be met in order to be eligible for the study: - Age 18-80 years- Documented long-term OCS therapy for asthma, equivalent to a daily dose of at least 5 mg and up to 40 mg of prednisone/prednisolone for at least 3 continuous months directly preceding Visit 1- Participant should be on a stable OCS dose for at least 4 weeks prior to Visit 1- Documented history of at least 1 asthma exacerbation event within 12 months prior" - Anonymous Online Contributor
Could you please elaborate on the potential risks of Tezepelumab?
"Tezepelumab is a medication that has completed Phase 3 clinical trials. This means there is available data which supports its efficacy and multiple rounds of data supporting safety. Our team at Power estimates the safety of Tezepelumab to be a 3 on a scale from 1 to 3." - Anonymous Online Contributor
Is this clinical trial happening at more than one hospital in the state?
"Currently, this trial is running at 8 sites. They are situated in Ann Arbor, Riverdale and Newark as well as 5 other locations. If you want to participate, it would be advantageous to choose the location nearest to you so that travelling isn't an inconvenience." - Anonymous Online Contributor
For this particular test, is the age limit set at 45 years or above?
"Enrolment for this study is open to patients aged between 18-80 years old. There are 117 clinical trials available for minors and 202 for senior citizens." - Anonymous Online Contributor
What goals does this research hope to achieve?
"The primary outcome that will be assessed at Week 52 is the percentage of patients who are able to reduce their daily maintenance oral corticosteroid dose to 5 mg/day or below without loss of asthma control. Additionally, researchers will also monitor the rate of hospitalization and emergency room visits due to exacerbations, as well as the overall number of exacerbations over the course of the trial." - Anonymous Online Contributor